Cookie policy notice

By continuing to use this site you agree to our cookies policy below:
Since 26 May 2011, the law now states that cookies on websites can ony be used with your specific consent. Cookies allow us to ensure that you enjoy the best browsing experience.

This site is intended for health professionals only

At the heart of general practice since 1960

Most gout patients not controlled with allopurinol

Three-quarters of patients with gout will not have their urate levels controlled by allopurinol, reports a Dutch study.

The researchers said these patients would have to be switched to a second treatment – although the most effective second-line option is not available in the UK.

In the study, 82 patients with gout received 300mg allopurinol for two months. But only 24% reached a target urate of 300[micro]g/l, while 11% stopped taking the drug due to adverse events.

The authors say: 'It seems that benzbromarone is a highly efficacious oral urate-lowering drug, which has been excessively withdrawn from the market. Reintroduction of benzbromarone in the market might be preferred instead of using new costly drugs, carrying a risk for unknown adverse drug reactions.

'Treatment of gout might be more successful with better – restricted - availability of benzbromarone.'

Annals of the Rheumatic Diseases 6 February early online publication

Rate this article 

Click to rate

  • 1 star out of 5
  • 2 stars out of 5
  • 3 stars out of 5
  • 4 stars out of 5
  • 5 stars out of 5

0 out of 5 stars

Have your say